Guidance

Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:
 the person has a forced vital capacity (FVC) between 50% and 80% of predicted  the company provides nintedanib with the discount agreed in the patient access scheme and  treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period.
1.2
People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. Investigator-reported acute exacerbations (according to the criteria described by the trial protocol); hazard ratio is based on analysis of time to first event c Source of pooled results: nintedanib summary of product characteristics (individual trial results were presented in the company submission) Key: CI, confidence interval; FVC, forced vital capacity; HR, hazard ratio; MD, mean difference; OR, odds ratio Subgroup analyses showed that there were no statistically significant differences between the effectiveness of nintedanib on slowing lung function decline in people with a percent predicted FVC of 50-80% and people with a percent predicted FVC of more than 80%.
3.4
To compare nintedanib with pirfenidone, the company did a network meta-analysis including the 3 nintedanib trials and 5 placebo-controlled trials of pirfenidone (SP2, SP3, CAPACITY 1, CAPACITY 2 and ASCEND) which informed its economic model.
The company chose different trials for different end points in the model:
 It included evidence from all the trials for overall survival.
 It excluded the 2 pirfenidone trials in Japanese populations (SP2 and SP3) for acute exacerbations, because of heterogeneity (differences compared with other studies, including longer disease duration and a different proportion of people who smoke).
 It excluded the ASCEND study of pirfenidone for decline in lung function.
The results are presented in Table 2 . The base-case results for overall survival were the same for nintedanib and pirfenidone, and neither drug showed a statistically significant difference in mortality compared with placebo. The base-case analysis of acute exacerbations showed comparable benefits for nintedanib and pirfenidone compared with placebo, but the company reported uncertainty in the results, which it considered to be a result of heterogeneity in the Japanese trials of pirfenidone (SP2 and SP3).
After excluding these trials from the network meta-analysis ('scenario 3' of the sensitivity analyses for this outcome), the results showed fewer acute exacerbations with nintedanib than
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Issue date: November 2015 pirfenidone. The company's analysis of loss of lung function (defined by the company as an absolute decline in percent predicted FVC of at least 10%) gave similar results for nintedanib and pirfenidone using the base-case network meta-analysis. The differences in loss of lung function between each drug and placebo were statistically significant. After excluding the ASCEND trial of pirfenidone from the network meta-analysis because of heterogeneity ('scenario 2' of the sensitivity analyses for this outcome), the results suggested that nintedanib was more effective than pirfenidone at reducing loss of lung function, however the company did not state whether this difference was statistically significant.
3.5
The company evaluated 4 safety outcomes in its network meta-analysis. It reported that, compared with people receiving placebo, those receiving nintedanib were more likely to have severe gastrointestinal events (p=0.055), stop the study drug (p=0.014), and have adverse events that led to stopping the study drug (p=0.007). These differences were statistically significant.
Nintedanib was associated with fewer serious cardiac events than placebo and pirfenidone, but the odds ratios were not statistically significant. Nintedanib was associated with more serious gastrointestinal events than pirfenidone (odds ratio 3.96, 95% 
ERG comments
3.6
The ERG highlighted that the 3 nintedanib trials enrolled people with a percent predicted FVC of at least 50% and therefore did not provide evidence for people with more severe disease.
3.7
The ERG was concerned that the company did not fully explain how lung function, physical function or acute exacerbations predict the course and outcome of the disease in patients. Therefore it was unclear which specific outcomes were the most clinically meaningful.
3.8
The ERG's key concern with the network meta-analysis was the potential for bias in favour of nintedanib because the company excluded studies in some scenarios.
Final appraisal determination -nintedanib for treating idiopathic pulmonary fibrosis  a log logistic model to estimate overall survival  an exponential model to estimate the probability of exacerbation and stopping medication  a logistic regression model to predict loss of lung function.
3.12
The company included adverse events in the model if they:
substantially affected costs and quality-adjusted life years (QALYs), had an incidence of more than 5%, or an incidence 1.5 times greater than in the comparator arm. The company excluded the adverse event diarrhoea, even though it occurred commonly in the INPULSIS trials (reported in over 60% of people receiving nintedanib compared with 19% of people receiving placebo), because the condition was usually mild to moderate in severity and resulted in less than 5% of people stopping treatment.
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3.19
The ERG suggested that the results of the company's cost-effectiveness analysis may have been biased, because the company chose a different scenario analysis from its network meta-analysis to inform the relative effectiveness of nintedanib and pirfenidone for each different outcome.
3.20
The ERG suggested that the company model overestimated disutilities for adverse events, and suggested alternative estimates, because:
 Adverse events in the company's model last for 1 year; the ERG considered that for gastrointestinal and skin disorders the duration would be shorter than this and suggested a duration of 1 month based on published data.
 Data from a long-term open-label extension study of the CAPACITY trials of pirfenidone (the RECAP study) suggested that the incidence of rash was lower than the estimates in the company model.  The company may have overestimated the incidence of photosensitivity associated with pirfenidone, which the ERG suggested patients can prevent by avoiding sun exposure.
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The ERG also noted the disutility associated with new exacerbations that the company included in its submission (−0.14)
did not match the disutility the company used in its model (0.0987).
Additional analyses
3.21
After consultation, the company increased the simple discount to the price of nintedanib. The company updated its analysis with the lower price and also included different results from the network meta-analysis in line with the Committee's preferred assumptions (see section 4.6). The company included all the trial evidence in the network meta-analysis for the outcomes of lung function, serious cardiac events, gastrointestinal events and probability of stopping the drug. The SP2 trial comparing pirfenidone with placebo in a Japanese population, which provided evidence in the network meta-analysis for overall survival and acute exacerbations, was considered to be an outlier by the Committee. Therefore the company excluded the SP2 study from the network meta-analysis for these outcomes. The company included a risk of death of 2.79% over 6 months for people with an exacerbation (previously the company did not model a link between exacerbation and life expectancy). It also reduced the duration of adverse events from 1 year to 1 month and corrected the disutility associated with new exacerbations (see section 4.11 for the Committee's preferred assumptions on disutilities). The company did not reduce the incidence of photosensitivity, but the ERG advised that this no longer affected the ICERs because the company had reduced the duration of adverse events to 1 month. As in the company's base case, the company modelled a population with percent predicted
4.4
The Committee discussed the treatment options for people with idiopathic pulmonary fibrosis.
 It heard that pirfenidone is normally offered to people whose disease meets the criteria in the NICE guidance for pirfenidone:
that is, people with a percent predicted FVC of 50-80%. It heard that this group represents around half of the population with idiopathic pulmonary fibrosis in the UK, but that around 30% of people could not tolerate pirfenidone.
Final appraisal determination -nintedanib for treating idiopathic pulmonary fibrosis provided an analysis in people with a percent predicted FVC of 80% or more. The Committee noted the ERG's concerns that subgroup analyses were subject to limitations because parameters such as hazard ratios, mortality rates, and rates of stopping treatment may differ between the subgroups and the whole population. In the absence of subgroup-specific parameters, the Committee concluded that the company model was appropriate for its decision-making.
4.9
The Committee considered the extrapolations of overall survival based on the company model. It noted that the company and the ERG had used the log logistic curve in their base-case analyses.
The Committee discussed whether this curve was appropriate
given that it has a long tail, meaning that the model might overestimate life expectancy and therefore underestimate the incremental cost-effectiveness ratio (ICER) for nintedanib. The
Committee noted that using other methods to extrapolate survival substantially increased the ICER for nintedanib compared with best supportive care. The Committee heard from the clinical experts that the median survival estimated with the log logistic curve generally reflects the natural history of treated disease. The Committee agreed that the survival modelling was uncertain, but noted that it had little effect on the ICER when comparing nintedanib with pirfenidone because the company had assumed equal survival with these drugs. Any differences in quality-adjusted life year (QALY) gain between nintedanib and pirfenidone were therefore derived from differences in quality of life. The Committee concluded that the log logistic curve was sufficient for decision-making, but recognised that the ICER for nintedanib compared with best supportive care, when using the log logistic curve, may be an underestimate.
4.10
The Committee discussed the utility values in the company's model. It approved of the company using trial-based EQ-5D data to
Final appraisal determination -nintedanib for treating idiopathic pulmonary fibrosis Committee concluded that it could not compare the models fully, but that the current model for nintedanib was robust, and appropriate for decision-making.
4.13
The Committee considered whether it should take into account the consequences of the Pharmaceutical Price Regulation Scheme the NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.
5.3
When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has idiopathic pulmonary fibrosis and the doctor responsible for their care thinks that nintedanib is the right treatment, it should be available for use, in line with NICE's recommendations.
5.4
The Department of Health and Boehringer Ingelheim have agreed that nintedanib will be available to the NHS with a patient access scheme which makes it available with a discount.  Slides highlighting key messages for local discussion.
 Costing template and report to estimate the national and local savings and costs associated with implementation.
 Implementation advice on how to put the guidance into practice and national initiatives that support this locally.
 A costing statement explaining the resource impact of this guidance.
 Audit support for monitoring local practice.
Related NICE guidance
Details are correct at the time of publication and will be removed when the final guidance is published. Further information is available on the NICE website.
Published
 Idiopathic pulmonary fibrosis in adults: diagnosis and management (2013) NICE guideline CG163. Therefore, should any changes be made to NICE technology appraisal guidance TA282, this guidance will be considered for review. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.  Boehringer Ingelheim
